Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03846687 · ClinicalTrials.gov registry record
Validation of Patient Reported Outcome Measures for Use in Hallux Valgus
A clinical trial of Hallux Valgus, sponsored by Ipsen.
- Completed
- Registry status
- 21
- Enrollment target
- 3
- Study locations
NCT03846687: Completed study of Hallux Valgus, sponsored by Ipsen.
NCT03846687 is a study of Hallux Valgus that has completed, run by Ipsen. The registered enrollment target is 21 participants, below the 79-participant average among 4 other Hallux Valgus trials with a reported enrollment target (73% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03846687, a study of Hallux Valgus, has completed, sponsored by Ipsen.
- COMPLETED
- Registry status
- 21 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of the study is to explore whether the mFFI is fit for purpose in adults with hallux valgus (HV).
Primary Outcome
Face-to-face interview (approx. 25 minutes), using semi-structured interview guide to explore the symptoms and impact of HV.
Conditions Studied
Study Locations (3)
California
- University Foot and Ankle Institute - Santa Monica
Ohio
- Ankle and Foot Care Centers - Youngstown
Texas
- Futuro Clinical Trials, LLC - McAllen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-10-30 |
| Est. Completion | 2020-01-15 |
What the finished NCT03846687 record still lists
NCT03846687 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 79-participant average among 4 other Hallux Valgus trials with a reported enrollment target (73% lower).
The record links to 1 condition, with Hallux Valgus appearing as the primary indexed condition, and to 0 interventions.
NCT03846687 reports a single indexed study location in California, Ohio, Texas.
Frequently Asked Questions
What is clinical trial NCT03846687 about?
NCT03846687 is a clinical study titled "Validation of Patient Reported Outcome Measures for Use in Hallux Valgus". The purpose of the study is to explore whether the mFFI is fit for purpose in adults with hallux valgus (HV).
What is the current status of trial NCT03846687?
This trial is currently completed. The enrollment target is 21 participants. The study started on 2018-10-30. Estimated completion is 2020-01-15.
What conditions does trial NCT03846687 study?
This clinical trial studies the following conditions: Hallux Valgus.
Who is sponsoring clinical trial NCT03846687?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03846687 being conducted?
This trial has 3 study locations across California, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hallux Valgus
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Outcomes Following Combined Adductoplasty™ and Lapiplasty® (MTA3D)
RECRUITING · NA
-
Early Weight-Bearing After the Lapiplasty Procedure
ACTIVE NOT RECRUITING · NA
-
Feasibility of an Analgesic Device Enabling Local Anesthetic Delivery and Neuromodulation After Shoulder/Foot Surgery
COMPLETED · NA
-
Patient Reported Function Following Combined First MTP and First TMT Arthrodesis.
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI